What you need to know
- NICE recommends lisdexamfetamine (Elvanse) or methylphenidate as first-line medication for adults with ADHD in the UK
- Titration typically takes 4 to 12 weeks to find the right medication and dose
- After a private diagnosis, your GP needs to agree to a shared care arrangement to manage your ongoing prescriptions on the NHS
- Without shared care, private prescriptions cost £80 to £200 per month
- With NHS shared care, you pay the standard prescription charge of £9.90 per item, or nothing if you are exempt
- Some GPs refuse shared care, which is why checking your surgery before your assessment matters
The part nobody explains
Getting an ADHD diagnosis is a significant moment. For many people it brings relief, clarity and finally an explanation for years of difficulty.
But the diagnosis is just the beginning of a process, not the end of one. What comes next, medication, titration, shared care, prescriptions, is where many people find themselves confused, unsupported and surprised by things nobody warned them about.
This guide explains exactly what happens after your ADHD diagnosis in the UK in 2026. Every medication named here is licensed for use in the UK. Every clinical detail is based on NICE Guideline NG87, the authoritative standard for ADHD diagnosis and management in England.
What happens immediately after your ADHD diagnosis
Whether you were diagnosed via the NHS, NHS Right to Choose or a private clinic, the immediate next steps are broadly the same.
Your diagnosing clinician will discuss medication options with you. They will take baseline measurements including blood pressure, heart rate and weight, since these are required by NICE guidelines before starting any ADHD medication.
If you are diagnosed privately, your clinic will typically manage the start of your medication and the titration process. At some point during or after titration, the question of shared care will arise. This is the arrangement under which your NHS GP takes over prescribing your repeat prescriptions, which significantly reduces your ongoing costs.
If you are diagnosed via the NHS or Right to Choose, your prescribing is managed within the NHS system from the start and shared care is less of an issue.
Types of ADHD medication available in the UK
ADHD medications in the UK fall into two broad categories: stimulants and non-stimulants. Here is a plain-English guide to what is available and what NICE recommends.
Stimulant medications
Stimulants work by increasing the levels of dopamine and noradrenaline in the prefrontal cortex, the part of the brain responsible for attention, impulse control and planning. They typically work within hours of the first dose and have the strongest evidence base of any ADHD treatment.
Lisdexamfetamine (Elvanse)
NICE guidelines recommend lisdexamfetamine as the first-line medication for adults with ADHD in the UK. It is a prodrug, meaning it is converted into its active form in the body after you take it, giving it a smoother onset and longer duration than some alternatives.
Elvanse is available in doses of 20mg, 30mg, 40mg, 50mg, 60mg and 70mg. It typically lasts 12 to 14 hours and is taken once daily in the morning.
Elvanse is a controlled drug (Schedule 2) in the UK. Prescriptions cannot be issued electronically, must be written on a paper FP10 form, and cannot cover more than 28 days supply at a time.
Methylphenidate
Methylphenidate is the most widely prescribed ADHD medication globally and NICE recommends it as a first-line option alongside lisdexamfetamine for adults. Several brands are available in the UK with different durations and release profiles.
| Brand name | Duration | Available doses |
|---|---|---|
| Concerta XL | Extended-release, 10–12 hrs | 18mg, 27mg, 36mg, 54mg. Once daily. |
| Medikinet XL | Modified-release, 8–10 hrs | 5, 10, 20, 30, 40, 50, 60mg. Once daily with breakfast. |
| Equasym XL | Modified-release, 6–8 hrs | 10, 20, 30mg. Sometimes used as afternoon top-up. |
| Ritalin | Immediate-release, 3–4 hrs | 10mg. Taken 2–3 times daily. |
Important: The MHRA issued a drug safety update in September 2022 advising caution when switching between modified-release methylphenidate products due to differences in formulations. Never switch brands without clinical supervision.
Like lisdexamfetamine, methylphenidate is a controlled drug subject to the same 28-day prescription rules.
Dexamfetamine
Dexamfetamine is considered a third-line option under NICE guidance. It may be prescribed if both lisdexamfetamine and methylphenidate have been tried and were either ineffective or not tolerated. It is an immediate-release medication taken 2 to 3 times daily.
Non-stimulant medications
Non-stimulant medications take several weeks to reach their full effect, rather than working within hours. They are typically used when stimulants are not tolerated, are contraindicated, or have not been effective.
Atomoxetine (Strattera)
Atomoxetine is a selective noradrenaline reuptake inhibitor. Unlike stimulants, it is not a controlled drug, meaning prescriptions can be issued electronically and for longer periods. It is taken once or twice daily and typically takes 4 to 6 weeks to show meaningful effect.
Guanfacine (Intuniv)
Guanfacine is licensed in the UK for children and adolescents aged 6 to 17. It is not typically a first-line option for adults. Your prescriber will advise whether it is appropriate for your situation.
What titration actually involves
Titration is the process of finding the right medication and the right dose for you. It is not a single prescription. It is a structured clinical process that takes weeks, involves regular monitoring, and requires honest communication between you and your prescriber throughout.
- 1Baseline measurements
Before starting any medication, your prescriber takes your baseline blood pressure, heart rate and weight. These are required by NICE guidelines and serve as your reference point for monitoring throughout titration.
- 2Starting dose
You start on a low dose of your chosen medication. The goal at this stage is not to find the right dose immediately but to see how your body responds and whether any side effects occur.
- 3Regular review
Every 1 to 2 weeks your prescriber will review how you are getting on, typically by phone or video. They will ask about symptom improvement, side effects, sleep and appetite. Based on your response they will maintain the current dose, increase it, or consider switching medication.
- 4Finding the right dose
This continues until you reach a dose where symptoms are meaningfully improved and any side effects are manageable.
- 5Ongoing monitoring
Blood pressure and weight monitoring is required throughout titration. NICE guidelines specify six-monthly checks once your dose is stable, and an annual review of whether medication remains beneficial.
How long titration takes
Four to twelve weeks is the typical window for reaching a stable dose, regardless of which medication class is used. Some people find the right medication and dose within four weeks. Others take longer, particularly if the first medication tried is not effective and a switch is needed.
Be patient with this process. Rushing titration by requesting early dose increases is counterproductive and increases the risk of side effects. The goal is the right dose, not the fastest dose.
If you are going through titration privately, be aware that once titration is complete the question of shared care becomes urgent. The sooner you begin that conversation with your GP, the sooner you can move to NHS prescribing and reduce your costs significantly.
What to do if your GP refuses shared care
- 1Ask for the refusal in writing
Ask your GP to provide their specific clinical reason for refusing in writing. Many GPs reconsider when asked to formally document a refusal that is not clinically grounded.
- 2Reference NHS England guidance
NHS England's Patient Choice Guidance states that GPs should not refuse shared care solely because a diagnosis was made privately, provided the diagnosing clinician is appropriately qualified.
- 3Use our free GP refusal letter
Our free GP refusal letter template generates a personalised letter citing NHS England guidance directly. It takes two minutes to complete and is ready to send to your GP immediately.
GP refused shared care?Get a free personalised letter citing NHS England guidance directly. Takes 2 minutes.
Get my refusal letter - 4Ask your diagnosing clinic for a shared care support letter
Most private ADHD clinics will write directly to your GP outlining the titration data and monitoring plan. This addresses many GPs' clinical concerns and often resolves a refusal.
- 5Escalate to your ICB
If your GP continues to refuse without a clinical reason, you can escalate to your Integrated Care Board. ICBs have a duty to investigate concerns about refusals of care that are not clinically justified.
The real cost of ADHD medication in the UK
Free if you are under 16, over 60, pregnant, on certain benefits, or hold a prepayment certificate. A prepayment certificate costs £32.05 per quarter or £111.60 per year and is worth buying if you have more than one prescription item per month.
Elvanse 50mg typically costs around £80 to £120 per month privately. Higher doses or less commonly available medications can cost significantly more.
A note on medication shortages: ADHD medication shortages have been a real and ongoing issue in the UK since 2022. Elvanse, Concerta XL and other commonly prescribed medications have at various points been in limited supply. If you experience a shortage, speak to your prescriber or pharmacist about equivalent available formulations. Do not switch between methylphenidate brands without clinical guidance given the MHRA warning on formulation differences.
What you can do today
See whether your surgery accepts shared care before you complete titration.
Check my GPGet a free personalised letter citing NHS England guidance.
Get my letterOur free 3-minute triage matches you to the right next step for your situation.
Start triageIf ADHD is affecting your work, you may be entitled to up to £69,260 a year in government-funded support.
See what I can claimNational Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline NG87. 2018 (updated 2019). nice.org.uk/guidance/ng87
MHRA Drug Safety Update. Methylphenidate long-acting modified-release preparations: caution if switching between products due to differences in formulations. September 2022. gov.uk drug safety update
NHS England. Patient Choice Guidance. Published 19 December 2023. england.nhs.uk patient choice guidance
NHS Business Services Authority. Prescription Prepayment Certificate. 2026. nhsbsa.nhs.uk PPC
Last reviewed: July 2026. This article is based on NICE Guideline NG87, NHS prescribing guidance and MHRA drug safety updates. It is intended as general information only and is not a substitute for medical advice. Always speak to your prescriber before making any changes to your medication.
